M
Maria E. Suarez-Almazor
Researcher at University of Texas MD Anderson Cancer Center
Publications - 215
Citations - 11320
Maria E. Suarez-Almazor is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Randomized controlled trial. The author has an hindex of 47, co-authored 214 publications receiving 8434 citations. Previous affiliations of Maria E. Suarez-Almazor include University of Copenhagen & McGill University.
Papers
More filters
Journal ArticleDOI
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh,Daniel E. Furst,Aseem Bharat,Jeffrey R. Curtis,Arthur Kavanaugh,Joel M. Kremer,Larry W. Moreland,James O'Dell,Kevin L. Winthrop,Timothy Beukelman,S. Louis Bridges,W. Winn Chatham,Harold E. Paulus,Maria E. Suarez-Almazor,Claire Bombardier,Maxime Dougados,Dinesh Khanna,Charles M. King,Amye L. Leong,Eric L. Matteson,John T. Schousboe,Eileen Moynihan,Karen S. Kolba,Archana Jain,Elizabeth R. Volkmann,Harsh Agrawal,Sangmee Bae,Amy S. Mudano,Nivedita M. Patkar,Kenneth G. Saag +29 more
TL;DR: The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Journal ArticleDOI
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Igor Puzanov,Adi Diab,K. Abdallah,Clifton O. Bingham,C. Brogdon,Ramona Dadu,Lamya Hamad,Sang Taek Kim,Mario E. Lacouture,Nicole R. LeBoeuf,D. Lenihan,C. Onofrei,Vickie R. Shannon,Rajeev Sharma,Ann W. Silk,Dimitra Skondra,Maria E. Suarez-Almazor,Yinghong Wang,K. Wiley,Howard L. Kaufman,Marc S. Ernstoff +20 more
TL;DR: A multidisciplinary Toxicity Management Working Group met for a full-day workshop to develop recommendations to standardize management of immune-related adverse events, and presents their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.
Journal ArticleDOI
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals,Julie R. Brahmer,Margaret K. Callahan,Margaret K. Callahan,Alejandra Flores-Chávez,Niamh M. Keegan,Munther A. Khamashta,Olivier Lambotte,Xavier Mariette,Aleix Prat,Maria E. Suarez-Almazor +10 more
TL;DR: This Primer by Ramos-Casals and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of immune-related adverse events and should be prescribed carefully to reduce the potential of short-term and long-term complications.
Journal ArticleDOI
Understanding the pain experience in hip and knee osteoarthritis – an OARSI/OMERACT initiative
Gillian A. Hawker,L. Stewart,M.R. French,Jolanda Cibere,Joanne M. Jordan,Lyn March,Lyn March,Maria E. Suarez-Almazor,Rachael Gooberman-Hill +8 more
TL;DR: Two distinct pain types were identified - a dull, aching pain which became more constant over time, punctuated increasingly with short episodes of a more intense, often unpredictable, emotionally draining pain and Intermittent intense pain, particularly when unpredictable, had the greatest impact on quality of life.
Journal ArticleDOI
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
TL;DR: Evidence from case reports shows that cancer patients develop irAEs following checkpoint blockade therapy, and can occasionally develop clearly defined autoimmune systemic diseases.